
Phase 3 biotech focused on rare diseases caused by mitochondrial dysfunction.
Industry: Health Care
First Day Return: -0.8%

| IPO Date | 02/14/2019 |
|---|---|
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $78 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| IPO Intelligence Only |
| Headquarters | Newton, MA, United States |
|---|---|
| Founded | 2006 |
| Employees at IPO | 57 |
| Website www.stealthbt.com | |